Targets › ROCK1
18 programs from 18 companies in 81 trials: 29 Phase 2, 23 Phase 3, 16 Phase 1, 13 Phase 4; Ophthalmology, Oncology, Immunology; next expected readout Nov 2026.
Protein kinase which is a key regulator of the actin cytoskeleton and cell polarity. Involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, TPPP, PFN1 and PPP1R12A. Phosphorylates FHOD1 and acts synergistically with it to promote…. (UniProt, Q13464)
Open in Phaseline: the race on ROCK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanofi | H5 Flu IMP 1 Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1, TNFSF4, CD38, IL4R | Phase 4 | RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic … | Dec 2026 |
| University of Maryland, Baltimore | Netarsudil Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 4 | Ocular Hypertension | Mar 2027 |
| Eye Centers of Southeast Texas | Netarsudil Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 4 | Glaucoma | May 2027 |
| Brett King | Netarsudil Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 4 | Open Angle Glaucoma (OAG) | Jan 2028 |
| Indiana University | Netarsudil Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 4 | Glaucoma | Jun 2028 |
| East Coast Institute for Research | Netarsudil Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 4 | Primary Open Angle Glaucoma or Ocular Hypertension | – |
| Marian Macsai, MD | Ripasudil hydrochloride hydrate 0.4% ophthalmic solution (Glanatec) ROCK inhibitor | ROCK1, ROCK2 | Phase 4 | Fuchs' Endothelial Dystrophy | – |
| Stanford University | Ripasudil Rho-kinase (ROCK) inhibitor | ROCK1, ROCK2 | Phase 3 | Fuchs | Nov 2026 |
| Aurion Biotech | Cryopreserved AURN001 Corneal endothelial cell therapy with Rho kinase inhibitor | ROCK1, ROCK2 | Phase 3 | Corneal Edema | Jun 2027 |
| Singapore Eye Research Institute | Ripasudil Rho kinase inhibitor | ROCK1, ROCK2 | Phase 3 | Fuchs' Endothelial Dystrophy | – |
| National Institute of Allergy and Infectious Diseases (NIAID) | Belumosudil Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 2 | Lung Transplant | May 2027 |
| Dana-Farber Cancer Institute | Belumosudil Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 2 | Bronchiolitis Obliterans Syndrome | Jun 2027 |
| Fred Hutchinson Cancer Center | Belumosudil Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 2 | Chronic Graft Versus Host Disease | Apr 2028 |
| Woolsey Pharmaceuticals | Fasudil (WP-0512) Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 2 | Amyotrophic Lateral Sclerosis; Prostate Cancer; Prostate CA; Cognitive Decline, Mild … | Jan 2029 |
| Memorial Sloan Kettering Cancer Center | Belumosudil Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 2 | Graft Versus Host Disease | May 2029 |
| M.D. Anderson Cancer Center | Belumosudil Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 1 | Multiple Myeloma; Chronic Graft Versus Host Disease | Aug 2027 |
| University of California, Los Angeles | Belumosudil (KD025) Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 1 | End Stage Kidney Disease | Aug 2028 |
| Massachusetts Eye and Ear Infirmary | Netarsudil Rho-associated protein kinase inhibitor | ROCK2, ROCK1 | Phase 1 | Rhegmatogenous Retinal Detachment | Sep 2028 |
Dermatitis Atopic (5) Chronic Graft Versus Host Disease (5) Colitis Ulcerative (4) Crohn's Disease (3) Plasma Cell Myeloma Refractory (3) Asthma (2) Hemophilia (2) Plasma Cell Myeloma (2) Ulcerative Colitis (2) Type 1 Diabetes Mellitus (2) Healthy Volunteers (2) Corneal Edema (2)
small molecule (15), protein or peptide (2)
Woolsey Pharmaceuticals (1) Sanofi (1) Massachusetts Eye and Ear Infirmary (1) Dana-Farber Cancer Institute (1) Aurion Biotech (1) University of California, Los Angeles (1) Stanford University (1) University of Maryland, Baltimore (1) Indiana University (1) Singapore Eye Research Institute (1) Marian Macsai, MD (1) Brett King (1) M.D. Anderson Cancer Center (1) East Coast Institute for Research (1) Memorial Sloan Kettering Cancer Center (1) Fred Hutchinson Cancer Center (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Eye Centers of Southeast Texas (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.